The drug, sold under the brand Leqembi, works by removing the toxic protein beta-amyloid from the brain, which aims to slow the progress of the neurodegenerative disease. Eisai plans to apply for marketing authorization in Japan and the European Union by the end of the year and estimates that the number of US patients eligible for the drug will reach around 100,000 within three years. Leqembi will be priced at $26,500 per year.
Eisai Applies for Full FDA Approval of Alzheimer's Drug Lecanemab
Eisai has applied for full FDA approval of its Alzheimer's drug, lecanemab, following its approval for use in the early stages of the disease. The drug, which is being developed in partnership with Biogen, will be sold under the brand Leqembi and works by removing sticky clumps of the toxic protein beta-amyloid from the brain to slow the progression of the neurodegenerative disease.
Eisai also plans to apply for marketing authorization in Japan and the European Union and estimates that the number of global patients eligible for the drug will reach around 2.5 million by 2030.
